IO Biotech, Inc.(IOBT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
IOBT Stock Analysis & AI Quality Score
AI stock analysis and institutional research for IO Biotech, Inc. (IOBT), a Healthcare sector company. IOBT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q3 2025), IO Biotech, Inc. reports net income of $-8.4M, free cash flow of $-18.5M. Top institutional holders of IOBT by reported 13-F value include Ikarian Capital,, BOOTHBAY FUND MANAGEMENT,, MARSHALL WACE, LLP, based on the most recent SEC filings. IOBT trades on the Nasdaq exchange and files with the SEC under CIK 1865494. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IOBT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IO Biotech, Inc. directly from SEC EDGAR.
Net Income
Q3 2025
$-8.4M
Free Cash Flow
Q3 2025
$-18.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-10.9% YoYOperating Income
-4.1% YoYEPS (Diluted)
+26.8% YoYTotal Assets
-55.1% YoYTotal Debt
Op. Cash Flow
-14.8% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Net Income | $-95.5M -10.9% | $-86.1M -20.5% | $-71.5M -5.3% | $-67.9M |
| Operating Income | $-95.2M -4.1% | $-91.4M -28.0% | $-71.4M -73.2% | $-41.2M |
| EPS (Diluted) | $-1.45 +26.8% | $-1.98 +20.2% | $-2.48 +85.7% | $-17.30 |
| Total Assets | $67.7M -55.1% | $150.7M -0.7% | $151.8M -31.7% | $222.3M |
| Total Debt | $0.00 | — | — | — |
| Operating Cash Flow | $-82.3M -14.8% | $-71.7M -20.1% | $-59.7M -46.9% | $-40.6M |
Get alerted when IOBT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for IO Biotech, Inc. including:
Top Institutional Holders of IOBT
Ikarian Capital, LLC
$81.4K1,386,565 shBOOTHBAY FUND MANAGEMENT, LLC
$26.5K451,852 shMARSHALL WACE, LLP
$18.1K301,291 shXTX Topco Ltd
$15.6K265,792 shMORGAN STANLEY
$12.1K206,215 shMILLENNIUM MANAGEMENT LLC
$11.4K194,158 shCITIGROUP INC
$4.3K72,495 shJANE STREET GROUP, LLC
$3.4K57,974 shBeacon Pointe Advisors, LLC
$2.5K42,600 shGEODE CAPITAL MANAGEMENT, LLC
$2.0K33,307 sh
| Fund | Value | Shares |
|---|---|---|
| Ikarian Capital, LLC | $81.4K | 1,386,565 |
| BOOTHBAY FUND MANAGEMENT, LLC | $26.5K | 451,852 |
| MARSHALL WACE, LLP | $18.1K | 301,291 |
| XTX Topco Ltd | $15.6K | 265,792 |
| MORGAN STANLEY | $12.1K | 206,215 |
| MILLENNIUM MANAGEMENT LLC | $11.4K | 194,158 |
| CITIGROUP INC | $4.3K | 72,495 |
| JANE STREET GROUP, LLC | $3.4K | 57,974 |
| Beacon Pointe Advisors, LLC | $2.5K | 42,600 |
| GEODE CAPITAL MANAGEMENT, LLC | $2.0K | 33,307 |
More Healthcare Companies
View all Healthcare →Put IOBT on your watchlist
Track score changes the day IO Biotech, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IOBT a good stock to buy?
13F Pro's AI-powered analysis of IO Biotech, Inc. (IOBT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IOBT are available on the IOBT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own IOBT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IOBT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IO Biotech, Inc.'s investment landscape.